Skip to main content
. 2016 Oct 4;9(6):302–310. doi: 10.1111/cts.12420

Figure 4.

Figure 4

Integrated plot of pharmacodynamic end points to compare exposure‐response of MYO‐029 in mice, monkeys, and humans. Data included projected coverage based on Kd, muscle weight increase post‐MYO‐029 treatment from an efficacy study in SCID mice, muscle circumference from a 39‐week toxicology study in monkeys, and predicted peak/trough levels of MYO‐029 in patients at steady‐state following 10 mg/kg biweekly i.v. doses.